BIOVENTUS INC. (BVS) Operating Margin
- Operating margin · 12 months: Value 10.02%; Formula and calculation Operating income / revenue. Period ending 2026-06-27..
Operating margin
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 10.02% | Operating income / revenue. Period ending 2026-06-27. $58.28M ÷ $581.85M × 100 ≈ 10.02% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 58.28M USD | Operating Income (Loss) |
| Revenue | 581.85M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 182.40M USD | Cost of Goods and Services Sold |
| Research and development | 11.57M USD | Research and Development Expense |
| Selling, general and administration | 322.48M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-27 | $58.28M | $581.85M | $182.40M | $11.57M | $322.48M | 10.02% |
| 2026-03-28 | $57.52M | $576.30M | $180.43M | $11.57M | $318.85M | 9.98% |
| 2025-12-31 | $53.98M | $568.09M | $179.93M | $12.11M | $314.03M | 9.50% |
| 2025-09-27 | $45.41M | $563.83M | $181.80M | $12.06M | $315.24M | 8.05% |
| 2025-06-28 | $37.80M | $564.14M | $182.79M | $12.98M | $318.06M | 6.70% |
| 2025-03-29 | $-12.04M | $567.70M | $184.80M | $14.02M | $335.62M | -2.12% |
| 2024-12-31 | $-11.98M | $573.28M | $185.05M | $13.64M | $340.89M | -2.09% |
| 2024-09-28 | $-18.80M | $555.06M | $183.19M | $13.65M | $332.64M | -3.39% |
| 2024-06-29 | $-20.46M | $536.89M | $179.72M | $12.86M | $321.37M | -3.81% |
| 2024-03-30 | $15.66M | $522.74M | $180.09M | $12.27M | $301.43M | 3.00% |
| 2023-12-31 | $-81.72M | $512.35M | $184.15M | $13.45M | $303.88M | -15.95% |
| 2023-09-30 | $-182.34M | $502.76M | $186.68M | $18.22M | $303.43M | -36.27% |
| 2023-07-01 | $-311.60M | $510.62M | $188.86M | $19.82M | $312.56M | -61.02% |
| 2023-04-01 | $-321.66M | $513.89M | $184.59M | $22.78M | $327.34M | -62.59% |
| 2022-12-31 | $-251.05M | $512.12M | $181.04M | $25.94M | $332.61M | -49.02% |
| 2022-10-01 | $-228.76M | $516.70M | $172.04M | $26.24M | $335.82M | -44.27% |
| 2022-07-02 | $-28.95M | $496.93M | $157.73M | $26.55M | $326.26M | -5.83% |
| 2022-04-02 | $-31.39M | $466.41M | $147.56M | $25.02M | $305.69M | -6.73% |
| 2021-12-31 | $12.06M | $430.90M | $128.19M | $19.04M | $254.25M | 2.80% |
| 2021-10-02 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-07-03 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-04-03 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $21.24M | $321.16M | $87.64M | $11.20M | $193.08M | 6.61% |
| 2020-09-26 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-27 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $31.19M | $340.14M | $90.94M | $11.05M | $198.47M | 9.17% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.